Antiparkinsonian activity of a non-ergot dopamine agonist, CV 205-502, in patients with fluctuating Parkinson's disease.
Six patients with fluctuating Parkinson's disease received single rising oral doses of the nonergot dopamine agonist CV 205-502 in an open experimental study. Doses of 0.5 mg produced antiparkinsonian effects of comparable intensity but longer duration than 200 mg of L-DOPA. CV 205-502, which combines structural features common to both ergolines and apomorphine, thus revealed interesting antiparkinsonian properties, but nausea and vomiting were dose-limiting side effects in all patients tested.
Poewe
W
W
Department of Neurology, University Hospital Innsbruck, Austria.
Luef
G
G
Kleedorfer
B
B
Emre
M
M
D000284:Administration, Oral; D000368:Aged; D000634:Aminoquinolines / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010302:Parkinson Disease, Secondary / Q000188:drug therapy*; D011954:Receptors, Dopamine / Q000187:drug effects*
D000634:Aminoquinolines; D011954:Receptors, Dopamine; C046650:quinagolide